Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 452

1.

Is there a role for HIPEC in ovarian cancer?

Harter P, du Bois A, Sehouli J, Mahner S, Vergote I, Chiva L, Gonzalez-Martin A, Fotopoulou C.

Arch Gynecol Obstet. 2018 Sep 20. doi: 10.1007/s00404-018-4908-0. [Epub ahead of print]

PMID:
30232581
2.

Checkpoint-inhibition in ovarian cancer: rising star or just a dream?

Pietzner K, Nasser S, Alavi S, Darb-Esfahani S, Passler M, Muallem MZ, Sehouli J.

J Gynecol Oncol. 2018 Nov;29(6):e93. doi: 10.3802/jgo.2018.29.e93. Review.

3.

Potential role of the HOXD8 transcription factor in cisplatin resistance and tumour metastasis in advanced epithelial ovarian cancer.

Sun P, Song Y, Liu D, Liu G, Mao X, Dong B, Braicu EI, Sehouli J.

Sci Rep. 2018 Sep 7;8(1):13483. doi: 10.1038/s41598-018-31030-3.

4.

The genetic landscape of 87 ovarian germ cell tumors.

Van Nieuwenhuysen E, Busschaert P, Neven P, Han SN, Moerman P, Liontos M, Papaspirou M, Kupryjanczyk J, Hogdall C, Hogdall E, Oaknin A, Garcia A, Mahner S, Trillsch F, Cibula D, Heitz F, Concin N, Speiser P, Salvesen H, Sehouli J, Lambrechts D, Vergote I.

Gynecol Oncol. 2018 Oct;151(1):61-68. doi: 10.1016/j.ygyno.2018.08.013. Epub 2018 Aug 28.

PMID:
30170975
5.

Participation of elderly gynecological cancer patients in clinical trials.

Prieske K, Trillsch F, Oskay-Özcelik G, Chekerov R, Bleich C, Oliveira-Ferrer L, Grimm D, Kuerti S, Mueller V, Suling A, Schmalfeldt B, Sehouli J, Mahner S, Woelber L.

Arch Gynecol Obstet. 2018 Oct;298(4):797-804. doi: 10.1007/s00404-018-4886-2. Epub 2018 Aug 30.

PMID:
30167853
6.

Clinical Significance of Organic Anion Transporting Polypeptide Gene Expression in High-Grade Serous Ovarian Cancer.

Svoboda M, Mungenast F, Gleiss A, Vergote I, Vanderstichele A, Sehouli J, Braicu E, Mahner S, Jäger W, Mechtcheriakova D, Cacsire-Tong D, Zeillinger R, Thalhammer T, Pils D.

Front Pharmacol. 2018 Aug 7;9:842. doi: 10.3389/fphar.2018.00842. eCollection 2018.

7.

Novel endocrine therapeutic strategy in endometrial carcinoma targeting estrogen-related receptor α by XCT790 and siRNA.

Sun P, Mao X, Gao M, Huang M, Chen L, Ruan G, Huang W, Braicu EI, Sehouli J.

Cancer Manag Res. 2018 Aug 10;10:2521-2535. doi: 10.2147/CMAR.S168043. eCollection 2018.

8.

Safety and dose modification for patients receiving niraparib.

Berek JS, Matulonis UA, Peen U, Ghatage P, Mahner S, Redondo A, Lesoin A, Colombo N, Vergote I, Rosengarten O, Ledermann J, Pineda M, Ellard S, Sehouli J, Gonzalez-Martin A, Berton-Rigaud D, Madry R, Reinthaller A, Hazard S, Guo W, Mirza MR.

Ann Oncol. 2018 Aug 13. doi: 10.1093/annonc/mdy255. [Epub ahead of print] No abstract available.

PMID:
30107447
9.

Sorafenib plus topotecan versus placebo plus topotecan for platinum-resistant ovarian cancer (TRIAS): a multicentre, randomised, double-blind, placebo-controlled, phase 2 trial.

Chekerov R, Hilpert F, Mahner S, El-Balat A, Harter P, De Gregorio N, Fridrich C, Markmann S, Potenberg J, Lorenz R, Oskay-Oezcelik G, Schmidt M, Krabisch P, Lueck HJ, Richter R, Braicu EI, du Bois A, Sehouli J; NOGGO; AGO TRIAS Investigators.

Lancet Oncol. 2018 Sep;19(9):1247-1258. doi: 10.1016/S1470-2045(18)30372-3. Epub 2018 Aug 9.

PMID:
30100379
10.

Clinical Outcome After Completion Surgery in Patients With Ovarian Cancer: The Charite Experience.

Babayeva A, Braicu EI, Grabowski JP, Gasimli K, Richter R, Muallem MZ, Sehouli J.

Int J Gynecol Cancer. 2018 Aug 7. doi: 10.1097/IGC.0000000000001328. [Epub ahead of print]

PMID:
30095708
11.

Preoperative CA-125 Value as a Predictive Factor for Postoperative Outcome in First Relapse of Platinum-sensitive Serous Ovarian Cancer.

Parashkevova A, Sehouli J, Richter R, Dimitrova D, Braicu EI, Muallem MZ.

Anticancer Res. 2018 Aug;38(8):4865-4870. doi: 10.21873/anticanres.12799.

PMID:
30061261
12.

Development of a Questionnaire for Monitoring Risk Factors for Chemotherapy-induced Nausea and Vomiting - A NOGGO Pilot Study.

Rittmeister H, Oskay-Özcelik G, Richter R, Sehouli J, Grabowski JP.

Anticancer Res. 2018 Aug;38(8):4859-4864. doi: 10.21873/anticanres.12798.

PMID:
30061260
13.

Preoperative Evaluation of Myometrial Invasion in Endometrial Carcinoma: Prospective Intra-individual Comparison of Magnetic Resonance Volumetry, Diffusion-weighted and Dynamic Contrast-enhanced Magnetic Resonance Imaging.

Thieme SF, Collettini F, Sehouli J, Biocca L, Lella A, Wagner M, Almuheimid J, Plett H, Muallem MZ.

Anticancer Res. 2018 Aug;38(8):4813-4817. doi: 10.21873/anticanres.12791.

PMID:
30061253
14.

Quality of life in patients with recurrent ovarian cancer treated with niraparib versus placebo (ENGOT-OV16/NOVA): results from a double-blind, phase 3, randomised controlled trial.

Oza AM, Matulonis UA, Malander S, Hudgens S, Sehouli J, Del Campo JM, Berton-Rigaud D, Banerjee S, Scambia G, Berek JS, Lund B, Tinker AV, Hilpert F, Vázquez IP, D'Hondt V, Benigno B, Provencher D, Buscema J, Agarwal S, Mirza MR.

Lancet Oncol. 2018 Aug;19(8):1117-1125. doi: 10.1016/S1470-2045(18)30333-4. Epub 2018 Jul 17.

PMID:
30026000
15.

Morphology and tumor-infiltrating lymphocytes in high-stage, high-grade serous ovarian carcinoma correlated with long-term survival.

Darb-Esfahani S, Kolaschinski I, Trillsch F, Mahner S, Concin N, Vergote I, Van Nieuwenhuysen E, Achimas-Cadariu P, Glajzer J, Woopen H, Wienert S, Taube ET, Stanske M, Kulbe H, Denkert C, Sehouli J, Braicu EI.

Histopathology. 2018 Jul 14. doi: 10.1111/his.13711. [Epub ahead of print]

PMID:
30007074
16.

Characterisation of tumour microvessel density during progression of high-grade serous ovarian cancer: clinico-pathological impact (an OCTIPS Consortium study).

Ruscito I, Cacsire Castillo-Tong D, Vergote I, Ignat I, Stanske M, Vanderstichele A, Glajzer J, Kulbe H, Trillsch F, Mustea A, Kreuzinger C, Benedetti Panici P, Gourley C, Gabra H, Nuti M, Taube ET, Kessler M, Sehouli J, Darb-Esfahani S, Braicu EI.

Br J Cancer. 2018 Aug;119(3):330-338. doi: 10.1038/s41416-018-0157-z. Epub 2018 Jun 29.

PMID:
29955134
17.

HIPEC: HOPE or HYPE in the fight against advanced ovarian cancer?

Fotopoulou C, Sehouli J, Mahner S, Harter P, Van Nieuwenhuysen E, Gonzalez-Martin A, Vergote I, Chiva L, Du Bois A.

Ann Oncol. 2018 Aug 1;29(8):1610-1613. doi: 10.1093/annonc/mdy198. No abstract available.

PMID:
29873689
18.

The Role of PAR1 Autoantibodies in Patients with Primary Epithelial Ovarian Cancer.

Kreienbring K, Franz A, Richter R, Dragun D, Heidecke H, Müller D, Mentze M, Dechend R, Sehouli J, Braicu EI.

Anticancer Res. 2018 Jun;38(6):3619-3625. doi: 10.21873/anticanres.12636.

PMID:
29848718
19.

Safety and dose modification for patients receiving niraparib.

Berek JS, Matulonis UA, Peen U, Ghatage P, Mahner S, Redondo A, Lesoin A, Colombo N, Vergote I, Rosengarten O, Ledermann J, Pineda M, Ellard S, Sehouli J, Gonzalez-Martin A, Berton-Rigaud D, Madry R, Reinthaller A, Hazard S, Guo W, Mirza MR.

Ann Oncol. 2018 Aug 1;29(8):1784-1792. doi: 10.1093/annonc/mdy181.

PMID:
29767688
20.

The prognostic impact of cancer stem-like cell biomarker aldehyde dehydrogenase-1 (ALDH1) in ovarian cancer: A meta-analysis.

Ruscito I, Darb-Esfahani S, Kulbe H, Bellati F, Zizzari IG, Rahimi Koshkaki H, Napoletano C, Caserta D, Rughetti A, Kessler M, Sehouli J, Nuti M, Braicu EI.

Gynecol Oncol. 2018 Jul;150(1):151-157. doi: 10.1016/j.ygyno.2018.05.006. Epub 2018 May 10.

PMID:
29753392
21.

The effects of short-term fasting on quality of life and tolerance to chemotherapy in patients with breast and ovarian cancer: a randomized cross-over pilot study.

Bauersfeld SP, Kessler CS, Wischnewsky M, Jaensch A, Steckhan N, Stange R, Kunz B, Brückner B, Sehouli J, Michalsen A.

BMC Cancer. 2018 Apr 27;18(1):476. doi: 10.1186/s12885-018-4353-2.

22.

Duration of storage influences the hemoglobin rising effect of red blood cells in patients undergoing major abdominal surgery.

Hunsicker O, Hessler K, Krannich A, Boemke W, Braicu I, Sehouli J, Meyer O, Pruß A, Spies C, Feldheiser A.

Transfusion. 2018 Aug;58(8):1870-1880. doi: 10.1111/trf.14627. Epub 2018 Apr 17.

PMID:
29665067
23.

Correction: Diagnostic markers for the detection of ovarian cancer in BRCA1 mutation carriers.

Gschwantler-Kaulich D, Weingartshofer S, Rappaport-Fürhauser C, Zeillinger R, Pils D, Muhr D, Braicu EI, Kastner MT, Tan YY, Semmler L, Sehouli J, Singer CF.

PLoS One. 2018 Apr 17;13(4):e0196142. doi: 10.1371/journal.pone.0196142. eCollection 2018.

24.

Trabectedin plus pegylated liposomal doxorubicin (PLD) for patients with platinum-sensitive recurrent ovarian cancer: a prospective, observational, multicenter study.

Runnebaum IB, Reichert D, Ringsdorf U, Kuther M, Hesse T, Sehouli J, Wimberger P.

J Cancer Res Clin Oncol. 2018 Jun;144(6):1185-1195. doi: 10.1007/s00432-018-2637-1. Epub 2018 Apr 6.

25.

Regulation of matriptase and HAI-1 system, a novel therapeutic target in human endometrial cancer cells.

Sun P, Xue L, Song Y, Mao X, Chen L, Dong B, Braicu EL, Sehouli J.

Oncotarget. 2018 Jan 3;9(16):12682-12694. doi: 10.18632/oncotarget.23913. eCollection 2018 Feb 27.

26.

[Expectation about maintenance therapy among the GINECO French ovarian cancer cohort from the European NOGGO/ENGOT-ov22 Expression IV survey].

Lorcet M, Lortholary A, Kurtz JE, Berton-Rigaud D, Fabbro M, De La Motte Rouge T, Kaminsky-Forrett MC, Floquet A, Freyer G, Combe P, Dohollou N, Kalbacher E, Despax R, Largillier R, Hardy Bessard AC, Gane N, Sehouli J, Oskay-Oezcelik G, Licaj I, Ray-Coquard I, Joly Lobbedez F.

Bull Cancer. 2018 May;105(5):465-474. doi: 10.1016/j.bulcan.2018.01.015. Epub 2018 Mar 12. French.

PMID:
29544693
27.

Immunobiochemical pathways of neopterin formation and tryptophan breakdown via indoleamine 2,3-dioxygenase correlate with circulating tumor cells in ovarian cancer patients- A study of the OVCAD consortium.

Gostner JM, Obermayr E, Braicu IE, Concin N, Mahner S, Vanderstichele A, Sehouli J, Vergote I, Fuchs D, Zeillinger R.

Gynecol Oncol. 2018 May;149(2):371-380. doi: 10.1016/j.ygyno.2018.02.020. Epub 2018 Mar 9.

PMID:
29530331
28.

Laparoscopic Neuronavigation for Deep Lateral Pelvic Endometriosis: Clinical and Surgical Implications.

Chiantera V, Petrillo M, Abesadze E, Sozzi G, Dessole M, Catello Di Donna M, Scambia G, Sehouli J, Mechsner S.

J Minim Invasive Gynecol. 2018 Mar 2. pii: S1553-4650(18)30145-6. doi: 10.1016/j.jmig.2018.02.015. [Epub ahead of print]

PMID:
29501810
29.

Dynamics of the Intratumoral Immune Response during Progression of High-Grade Serous Ovarian Cancer.

Stanske M, Wienert S, Castillo-Tong DC, Kreuzinger C, Vergote I, Lambrechts S, Gabra H, Gourley C, Ganapathi RN, Kolaschinski I, Budczies J, Sehouli J, Ruscito I, Denkert C, Kulbe H, Schmitt W, Jöhrens K, Braicu I, Darb-Esfahani S.

Neoplasia. 2018 Mar;20(3):280-288. doi: 10.1016/j.neo.2018.01.007. Epub 2018 Feb 22.

30.
31.

The role of bevacizumab in targeted vascular endothelial growth factor therapy for epithelial ovarian cancer: an updated systematic review and meta-analysis.

Ruan G, Ye L, Liu G, An J, Sehouli J, Sun P.

Onco Targets Ther. 2018 Jan 23;11:521-528. doi: 10.2147/OTT.S155581. eCollection 2018.

32.

Expression III: patients' expectations and preferences regarding physician-patient relationship and clinical management-results of the international NOGGO/ENGOT-ov4-GCIG study in 1830 ovarian cancer patients from European countries.

Oskay-Özcelik G, Alavi S, Richter R, Keller M, Chekerov R, Cecere SC, Cormio G, Joly F, Kurtz JE, du Bois A, Maciejewski M, Jedryka M, Vergote I, Van Nieuwenhuysen E, Casado A, Mendiola C, Achimas-Cadariu P, Vlad C, Reimer D, Zeimet AG, Friedlander M, Sehouli J.

Ann Oncol. 2018 Apr 1;29(4):910-916. doi: 10.1093/annonc/mdy037.

PMID:
29415128
33.

HOXA4/HOXB3 gene expression signature as a biomarker of recurrence in patients with high-grade serous ovarian cancer following primary cytoreductive surgery and first-line adjuvant chemotherapy.

Miller KR, Patel JN, Zhang Q, Norris EJ, Symanowski J, Michener C, Sehouli J, Braicu I, Destephanis DD, Sutker AP, Jones W, Livasy CA, Biscotti C, Ganapathi RN, Tait DL, Ganapathi MK.

Gynecol Oncol. 2018 Apr;149(1):155-162. doi: 10.1016/j.ygyno.2018.01.022.

PMID:
29402501
34.

Risk factors for 30-day complications after cancer surgery in geriatric patients: a secondary analysis.

Scholtz K, Spies CD, Mörgeli R, Eckardt R, von Dossow V, Braun S, Sehouli J, Bahra M, Stief CG, Wernecke KD, Schmidt M; PERATECS Group.

Acta Anaesthesiol Scand. 2018 Apr;62(4):451-463. doi: 10.1111/aas.13067. Epub 2018 Jan 22.

PMID:
29359461
35.

The use of PIPAC (pressurized intraperitoneal aerosol chemotherapy) in gynecological oncology: a statement by the German "Arbeitsgemeinschaft Gynaekologische Onkologie Studiengruppe Ovarialkarzinom (AGO-OVAR)", the Swiss and Austrian AGO, and the North-Eastern German Society of Gynaecologic Oncology.

Dueckelmann AM, Fink D, Harter P, Heinzelmann V, Marth C, Mueller M, Reinthaller A, Tamussino K, Wimberger P, Sehouli J.

Arch Gynecol Obstet. 2018 Apr;297(4):837-846. doi: 10.1007/s00404-018-4673-0. Epub 2018 Jan 22. Review. Erratum in: Arch Gynecol Obstet. 2018 Feb 14;:.

PMID:
29356953
36.

[Ichthyosis uteri (psoriasis uteri) : A very rare disorder].

von Laffert M, Elezkurtaj S, Sehouli J, Barinoff J, Boschetti Grützmacher E, Arsenic R, Bläker H.

Pathologe. 2018 May;39(3):264-268. doi: 10.1007/s00292-017-0403-9. German.

PMID:
29313082
37.

Circulating tumor cells: potential markers of minimal residual disease in ovarian cancer? a study of the OVCAD consortium.

Obermayr E, Bednarz-Knoll N, Orsetti B, Weier HU, Lambrechts S, Castillo-Tong DC, Reinthaller A, Braicu EI, Mahner S, Sehouli J, Vergote I, Theillet C, Zeillinger R, Brandt B.

Oncotarget. 2017 Nov 16;8(63):106415-106428. doi: 10.18632/oncotarget.22468. eCollection 2017 Dec 5.

38.

High-grade ovarian serous carcinoma patients exhibit profound alterations in lipid metabolism.

Braicu EI, Darb-Esfahani S, Schmitt WD, Koistinen KM, Heiskanen L, Pöhö P, Budczies J, Kuhberg M, Dietel M, Frezza C, Denkert C, Sehouli J, Hilvo M.

Oncotarget. 2017 Oct 26;8(61):102912-102922. doi: 10.18632/oncotarget.22076. eCollection 2017 Nov 28.

39.

Measuring what matters MOST: validation of the Measure of Ovarian Symptoms and Treatment, a patient-reported outcome measure of symptom burden and impact of chemotherapy in recurrent ovarian cancer.

King MT, Stockler MR, O'Connell RL, Buizen L, Joly F, Lanceley A, Hilpert F, Okamoto A, Aotani E, Bryce J, Donnellan P, Oza A, Avall-Lundqvist E, Berek JS, Sehouli J, Feeney A, Berton-Rigaud D, Costa DSJ, Friedlander ML; GCIG Symptom Benefit group.

Qual Life Res. 2018 Jan;27(1):59-74. doi: 10.1007/s11136-017-1729-8. Epub 2017 Dec 16.

PMID:
29248998
40.

Diagnostic markers for the detection of ovarian cancer in BRCA1 mutation carriers.

Gschwantler-Kaulich D, Weingartshofer S, Rappaport-Fürhauser C, Zeillinger R, Pils D, Muhr D, Braicu EI, Kastner MT, Tan YY, Semmler L, Sehouli J, Singer CF.

PLoS One. 2017 Dec 15;12(12):e0189641. doi: 10.1371/journal.pone.0189641. eCollection 2017. Erratum in: PLoS One. 2018 Apr 17;13(4):e0196142.

41.

Cytoreductive surgery for ovarian cancer: quality assessment.

Brand AH, DiSilvestro PA, Sehouli J, Berek JS.

Ann Oncol. 2017 Nov 1;28(suppl_8):viii25-viii29. doi: 10.1093/annonc/mdx448. Review.

PMID:
29232471
42.

Rare ovarian tumours: Epidemiology, treatment challenges in and outside a network setting.

Ray-Coquard I, Trama A, Seckl MJ, Fotopoulou C, Pautier P, Pignata S, Kristensen G, Mangili G, Falconer H, Massuger L, Sehouli J, Pujade-Lauraine E, Lorusso D, Amant F, Rokkones E, Vergote I, Ledermann JA; RARECARENet Working Group.

Eur J Surg Oncol. 2017 Nov 3. pii: S0748-7983(17)30947-2. doi: 10.1016/j.ejso.2017.09.025. [Epub ahead of print]

PMID:
29108961
43.

Validation of the modified Glasgow Prognostic Score (mGPS) in recurrent ovarian cancer (ROC) - Analysis of patients enrolled in the GCIG Symptom Benefit Study (SBS).

Roncolato FT, Berton-Rigaud D, O'Connell R, Lanceley A, Sehouli J, Buizen L, Okamoto A, Aotani E, Lorusso D, Donnellan P, Oza A, Avall-Lundqvist E, Berek J, Hilpert F, Ledermann JA, Kaminsky MC, Stockler MR, King MT, Friedlander M.

Gynecol Oncol. 2018 Jan;148(1):36-41. doi: 10.1016/j.ygyno.2017.10.019. Epub 2017 Oct 26.

PMID:
29107348
44.

Prediction of clinical response to drugs in ovarian cancer using the chemotherapy resistance test (CTR-test).

Kischkel FC, Meyer C, Eich J, Nassir M, Mentze M, Braicu I, Kopp-Schneider A, Sehouli J.

J Ovarian Res. 2017 Oct 27;10(1):72. doi: 10.1186/s13048-017-0365-9.

45.

The growth of uterine myomas in untreated women: influence factors and ultrasound monitoring.

Armbrust R, Wernecke KD, Sehouli J, David M.

Arch Gynecol Obstet. 2018 Jan;297(1):131-137. doi: 10.1007/s00404-017-4568-5. Epub 2017 Oct 23.

PMID:
29063234
46.

Prevalence of deleterious germline variants in risk genes including BRCA1/2 in consecutive ovarian cancer patients (AGO-TR-1).

Harter P, Hauke J, Heitz F, Reuss A, Kommoss S, Marmé F, Heimbach A, Prieske K, Richters L, Burges A, Neidhardt G, de Gregorio N, El-Balat A, Hilpert F, Meier W, Kimmig R, Kast K, Sehouli J, Baumann K, Jackisch C, Park-Simon TW, Hanker L, Kröber S, Pfisterer J, Gevensleben H, Schnelzer A, Dietrich D, Neunhöffer T, Krockenberger M, Brucker SY, Nürnberg P, Thiele H, Altmüller J, Lamla J, Elser G, du Bois A, Hahnen E, Schmutzler R.

PLoS One. 2017 Oct 20;12(10):e0186043. doi: 10.1371/journal.pone.0186043. eCollection 2017.

47.

Incidence Patterns and Survival of Gynecological Sarcoma in Germany: Analysis of Population-Based Cancer Registry Data on 1066 Women.

Pietzner K, Buttmann-Schweiger N, Sehouli J, Kraywinkel K.

Int J Gynecol Cancer. 2018 Jan;28(1):134-138. doi: 10.1097/IGC.0000000000001128.

PMID:
29040191
48.

The Impact of Surgical Staging on the Prognosis of Mucinous Borderline Tumors of the Ovaries: A Multicenter Study.

Gungorduk K, Asicioglu O, Braicu EI, Almuheimid J, Gokulu SG, Cetinkaya N, Gungor T, Pakay G, Telli EU, Cuylan ZF, Toptas T, Bilgi A, Ozyurt R, Agacayak E, Ozdemir A, Yildirim N, Taskin S, Oge T, Erol O, Akman L, Turan A, Icen MS, Senol T, Ovali OI, Yucesoy B, Gungorduk O, Temizkan O, Sanci M, Simsek T, Meydanli MM, Harma M, Yasar L, Uysal AD, Karateke A, Ortac F, Ozalp SS, Sehouli J, Muallem MZ.

Anticancer Res. 2017 Oct;37(10):5609-5616.

PMID:
28982877
49.

A Complex Network of Tumor Microenvironment in Human High-Grade Serous Ovarian Cancer.

Kreuzinger C, Geroldinger A, Smeets D, Braicu EI, Sehouli J, Koller J, Wolf A, Darb-Esfahani S, Joehrens K, Vergote I, Vanderstichele A, Boeckx B, Lambrechts D, Gabra H, Wisman GBA, Trillsch F, Heinze G, Horvat R, Polterauer S, Berns E, Theillet C, Cacsire Castillo-Tong D.

Clin Cancer Res. 2017 Dec 15;23(24):7621-7632. doi: 10.1158/1078-0432.CCR-17-1159. Epub 2017 Oct 2.

PMID:
28972047
50.

Vulvar cancer in Germany: increase in incidence and change in tumour biological characteristics from 1974 to 2013.

Holleczek B, Sehouli J, Barinoff J.

Acta Oncol. 2018 Mar;57(3):324-330. doi: 10.1080/0284186X.2017.1360513. Epub 2017 Aug 11.

PMID:
28799431

Supplemental Content

Loading ...
Support Center